• If you are having problems logging in please use the Contact Us in the lower right hand corner of the forum page for assistance.

Bad food makes good money

Help Support Ranchers.net:

Sandhusker

Well-known member
Joined
Feb 10, 2005
Messages
18,486
Reaction score
0
Location
Nebraska
SAN FRANCISCO (AP) — A girl fell into a 40-day coma after eating a bad Jack in the Box hamburger. Fifteen years later, she is still suffering ill effects. That doesn't bode well for a toddler who spent six weeks in the hospital in 2006 after eating E. coli-tainted spinach from California.

William MarlerBut both have lawyer William Marler in their corner — and that's no small consolation.

The Seattle-based Marler is the undisputed king of food poisoning litigation. He has made good money from bad food, ringing up more than $300 million in settlements for his clients in the rapidly growing legal field of food safety.

"There is a sense of complacency in the meat industry that believes, 'Hey, we solved that problem, and we don't have to watch it so much,"' said Marler, whose career has proved otherwise.

The Centers for Disease Control and Prevention estimates that food poisoning each year afflicts some 76 million Americans; 300,000 require hospitalization and 5,000 die.

Many victims end up hiring Marler, who took his first food poisoning case in 1993, during the Jack in the Box E. coli outbreak in the Pacific Northwest. That outbreak sickened hundreds of people and killed four children.

The past year has been a busy one for Marler's six-lawyer firm, which has about 1,000 active cases in all 50 states. The clients typically pay their lawyers 25 to 35 percent of their settlements.

The targets of Marler's lawsuits include the Topps Meat Co., which recalled 21.7 million pounds of its hamburger patties in September — the second-biggest U.S. beef recall ever — then went out of business. When Cargill Inc. recalled 840,000 pounds of beef patties the following month, it brought more lawsuits by Marler.

He is also suing ConAgra Foods Inc., which recalled its Banquet chicken pot pies and Peter Pan peanut butter last year after they were found to be contaminated with salmonella.

"He's a good lawyer, and he does a fine job for his clients," said Leo Knowles, ConAgra's top lawyer. "He's passionate about food safety. At times he's a little bit overly dramatic, but I think he's genuine."

"Bill was certainly at the right place at the right time entering the field of food safety litigation," said Caroline Smith DeWaal, who is in charge of food safety at the nonprofit Center for Science in the Public Interest in Washington. "I see him in kind of a private attorney general role."

Marler, 50, operates three dozen Web sites dedicated to food-borne illnesses. He is a tireless blogger on all things food safety and appears in front of federal and state lawmakers and regulatory boards. The license plate on his wife's Volkswagen reads ECOLI.

In all these cases, Marler has gone to trial just once, winning a $4.6 million verdict against a Washington state school district where 11 children got E. coli poisoning in the cafeteria.

Instead, he adroitly uses his sympathetic clients — and the media — to shame food producers into settling.

"I don't apologize for that," he said. "The publicity helps generate change."

Marler fell into food safety litigation almost by accident.

Brianne Kiner, 9, of Seattle was the first among hundreds who fell ill in the Jack in the Box outbreak. Six lawyers trekked to her bedside during the six months she spent in the hospital, hoping to represent the family. The Kiners hired Marler, a young associate at a midsize law firm who had never worked on a food case.

"I wanted a young, hungry lion," recalls Suzanne Kiner, Brianne's mother. "He was also the only one who looked at her and teared up."

Marler said: "When I started doing the Jack in the Box case in 1993, I never dreamed that I would be doing this in 2008. . ."
 
Just makes you wonder if and when the tracing of cattle back to the pasture will create a complete cottage industry of forcing these types of litigations all the way back to the ranch and feedlots?

Of course on the other hand, the tracing back of cattle whose record was clean could save the day also.
 
Does anyone know the percentage of cattle going into packing plants carrying e coli 0157:H7? Or percentage of cattle carrying it off the producers' premises?

What happens when packers refuse to accept cattle carrying it?

mrj
 
mrj said:
Does anyone know the percentage of cattle going into packing plants carrying e coli 0157:H7? Or percentage of cattle carrying it off the producers' premises?

What happens when packers refuse to accept cattle carrying it?

mrj

Then they won't be buying any cattle.

The real question is what happens when consumers refuse to buy beef because they afraid of getting sick?
 
Mike said:
Just makes you wonder if and when the tracing of cattle back to the pasture will create a complete cottage industry of forcing these types of litigations all the way back to the ranch and feedlots?

Of course on the other hand, the tracing back of cattle whose record was clean could save the day also.

Also makes you wonder what family farm/ranch/feedlot will have the cribs of attorneys- and unlimited court costs to challenge these litigations if the Multinational Corporates want to point the finger away from themselves- and at the guy at the bottom of the proverbial hill (cattleman/feeder).....

As has been shown in many past cases- USDA/FDA who are supposed to make those unbiased investigations and decisions are already in the pockets of the few with unlimited political influence (money)........ :( :( :mad:
 
mrj said:
Does anyone know the percentage of cattle going into packing plants carrying e coli 0157:H7? Or percentage of cattle carrying it off the producers' premises?

What happens when packers refuse to accept cattle carrying it?

mrj
mrj, why are you intent on blaming producers(or consumers) for contaminating meat with E.coli 0157:H7? Your logic is the same as blaming the store owner for selling a gun and ammo that is later stolen and used in a crime! Even if the cattle are infected with 0157:H7 when they come off the ranch or feedlot, the meat isn't contaminated...that happens after the producer gives up responsibility. Why are you unwilling to place blame where contamination of meat is MOST LIKELY TO OCCUR...ON THE KILL FLOOR? :? :???:

"Sound science" says E.coli 0157:H7 is a product of acid rumen environment...to reduce it, the industry would have to stop using feeds that cause acid rumens! :shock: :roll:
 
When did I ever blame producers for contaminating meat with e coli (and, yes, when I say e coli, it is E. coli 0157:H7, I'm simply taking a shortcut)?

I do say, it can't get into the meat if it doesn't come into the plant.

Are you claiming you do not have e coli in your part of the country?

If it is ONLY from an 'acid rumen' as you imply, why has it been found in deer feces, among other wild animals, and in animals not fed grain????

My point is that e coli is a problem for everyone in the industry, and it seems reasonable to me that all of us are working to find solutions to the problem.

Some of you here seem to find it more fun to simply blame packers for everything rather than put any effort into solving problems.

mrj
 
Mike Quote;Just makes you wonder if and when the tracing of cattle back to the pasture will create a complete cottage industry of forcing these types of litigations all the way back to the ranch and feedlots? ****** Their are lawyers waiting in the wings.

Of course on the other hand, the tracing back of cattle whose record was clean could save the day also.**** That's what ScoringAg proves everyday via US. code 21 CFR part 11 of traceback proof and verification.
 
The raw material for this vaccine is produced about 2 miles from me.



BELLEVILLE, ON, Feb. 5 /PRNewswire-FirstCall/ - Bioniche Life Sciences
Inc. (TSX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today received notice from the United States
Department of Agriculture (USDA) that the latest data for its E. coli
O157:H7 cattle vaccine "meets the 'expectation of efficacy' standard" and
is eligible for a conditional license, providing that the Company develops
a plan "that would collect sufficient data to move the product to full
licensure". The conditional license, when granted, will provide the Company
full access to the U.S. market with two restrictions: At least one step in
the manufacturing process must be performed in the United States and
Bioniche will not be permitted to use a trademark name for the vaccine.

The Bioniche vaccine is the world's first vaccine that may be used as
an on-farm intervention to reduce the amount of E. coli O157:H7 shed by
cattle. Bioniche and its collaborators have been moving the vaccine towards
commercial availability for eight years and it has been extensively tested
at the University Nebraska-Lincoln, with efficacy results now being
published in peer-reviewed scientific journals, most recently, the Journal
of Food Protection, in November, 2007. The E. coli O157:H7 cattle vaccine
will be manufactured in the Bioniche production facility in Belleville,
Ontario, Canada where a two-year, $25 million expansion is taking place.
Vaccine supply will be limited during this manufacturing expansion period.

"This is a large step forward for the E. coli O157:H7 vaccine," said
Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "The granting
of a U.S. conditional license will permit U.S. beef and dairy producers
access to a scientifically-validated means to reduce the risk of E. coli
O157:H7 contamination."

Rick Culbert, President of Bioniche Food Safety, added, "There are an
estimated 97 million cattle in the United States, many of which carry and
shed E. coli O157:H7. We look forward to working with producers to
implement vaccination as the first licensed on-farm intervention for E.
coli risk reduction."

In order to begin providing vaccine to U.S cattle producers, the
Company is required to produce three validated production lots, which will
be filled in the United States, in accordance with the Virus-Serum-Toxin
Act of 1913, as amended 1985.

It has taken some months for USDA reviewers to complete their
assessment of vaccine efficacy data against a pathogen with a complex life
cycle in variable real-world environments. Both the USDA and Bioniche have
been diligently working through these challenging issues with a view to
benefiting public health and the cattle industry. "We are very pleased that
the USDA reviewers recognize the scientific merit and importance to the
market of this vaccine," added Mr. McRae. "The vaccine is especially novel
in that it reduces shedding of an organism that, while potentially lethal
to humans, causes no disease in cattle. As a result, it was particularly
challenging for regulators - understanding the many implications of this
vaccine as a tool in reducing the shedding and colonization of E. coli
O157:H7 in cattle."

Food recalls due to E. coli O157:H7 contamination continue to be a
concern in beef, produce and prepared food. On-farm interventions to reduce
the shedding of E. coli O157:H7 by cattle, such as vaccination, may assist
in reducing the potential for food and water contamination and the
resulting human illnesses and deaths.

Approximately 100,000 cases of human infection with the E. coli O157:H7
organism are reported each year in North America. 2% to 7% of those people
develop hemolytic uremic syndrome (HUS), a disease characterized by kidney
failure (in recent outbreaks, this percentage has risen to as high as 16%).
Five percent of HUS patients die, many of them children and senior
citizens, whose kidneys are more sensitive to damage.

In addition to being infected by contaminated food or water,
individuals can become infected from E. coli O157:H7 by visiting animal
exhibits. Petting zoos, fairs, and agricultural exhibits provide many
possible routes of transmission for E. coli. Direct animal contact is the
obvious route, but contact with contaminated products (e.g., sawdust,
shavings, soiled clothing or shoes) can also lead to human infection.

About the E. coli O157:H7 Cattle Vaccine

This vaccine received international recognition in September, 2007 by
the Animal Pharm Industry Excellence Awards as the best new veterinary
product for livestock globally. The vaccine has been developed by a
strategic alliance formed in 2000 between the University of British
Columbia (UBC), the Alberta Research Council (ARC), the University of
Saskatchewan's Vaccine & Infectious Disease Organization (VIDO), and
Bioniche, which holds the rights for worldwide commercialization of the
vaccine. The vaccine prevents the E. coli O157:H7 bacteria from attaching
to the intestines of vaccinated cattle, thereby reducing their reproduction
within the animal, and reducing the amount of bacteria that can be released
through cattle manure in the environment. More than 30,000 cattle have been
involved in clinical testing of the vaccine over the past five years.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs
approximately 200 skilled personnel and has three operating divisions:
Human Health, Animal Health, and Food Safety. The Company's primary goal is
to develop proprietary cancer therapies supported by revenues from marketed
products in human and animal health. Bioniche has been named one of
Canada's Top Ten Life Sciences Companies for 2008. For more information,
please visit http://www.Bioniche.com.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products
and pricing, new product development, uncertainties related to the
regulatory approval process, and other risks detailed from time to time in
the Company's ongoing quarterly and annual reporting.
 
added Mr. McRae. "The vaccine is especially novel
in that it reduces shedding of an organism that, while potentially lethal
to humans, causes no disease in cattle.
 
DaleK the vaccine was actually develpoed in Saskatchewan on the campus of the University of saskatchewan at the VIDO lab when i was a summer student employee and is being taken to market by Bioniche. Friends still working at Vido tell me that they are working on a nasal delivery system that makes vaccination easier.
 
From what I understand they're collecting antibodies from horses infected with E.Coli then refining them to produce the vaccine for cattle. The horses are just up the road here, run around on pasture all the time and every X days get taken into a lab on the farm and have some blood drawn or whatever, then back out on the pastures. Looks like a pretty good life.
 

Latest posts

Top